Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED Phase 3

A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Participants >=12 Years Old With Persistent Asthma

NCT02031640 · View on ClinicalTrials.gov ↗

Study Summary

This is a Phase 3, randomized, placebo-controlled, double-blind,double-dummy, parallel-group, 12-week study in male and female patients, 12 years of age and older, with persistent asthma.

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG Albuterol/salbutamol
  • DRUG Beclomethasone dipropionate

Study Locations (20)

California

  • Teva Investigational Site 10851 — Costa Mesa
  • Teva Investigational Site 10849 — Huntington Beach
  • Teva Investigational Site 10872 — Huntington Beach
  • Teva Investigational Site 10833 — Long Beach
  • Teva Investigational Site 10861 — Los Angeles
  • Teva Investigational Site 10798 — Mission Viejo
  • Teva Investigational Site 10806 — Orange
  • Teva Investigational Site 10828 — Orange
  • Teva Investigational Site 10860 — Paramount
  • Teva Investigational Site 10813 — Rancho Mirage
  • Teva Investigational Site 10843 — Riverside
  • Teva Investigational Site 10857 — Rolling Hills Estates
  • Teva Investigational Site 10847 — San Diego
  • Teva Investigational Site 10871 — San Diego
  • Teva Investigational Site 10876 — San Jose
  • Teva Investigational Site 12270 — Walnut Creek

Colorado

  • Teva Investigational Site 12266 — Centennial
  • Teva Investigational Site 10838 — Colorado Springs
  • Teva Investigational Site 10844 — Denver
  • Teva Investigational Site 10799 — Wheat Ridge

Trial Details

FieldValue
Enrollment Target 1,113 participants
Start Date 2013-12
Est. Completion 2014-12
Phase Phase 3

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02031640

The ClinicalTrials.gov registry entry for NCT02031640 describes a study currently listed as completed. It is categorized as Phase 3, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 1,113 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Teva Branded Pharmaceutical Products R&D, which has 103 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Asthma appearing as the primary indexed condition, and to 3 interventions — of which Placebo is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT02031640 reports 20 study locations spanning 2 distinct geographic areas — top geographies include California, Colorado. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT02031640 about?

NCT02031640 is a clinical study titled "A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Participants >=12 Years Old With Persistent Asthma". This is a Phase 3, randomized, placebo-controlled, double-blind,double-dummy, parallel-group, 12-week study in male and female patients, 12 years of age and older, with persistent asthma.

What is the current status of trial NCT02031640?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,113 participants. The study started on 2013-12. Estimated completion is 2014-12.

What conditions does trial NCT02031640 study?

This clinical trial studies the following conditions: Asthma. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT02031640?

The interventions under investigation include: Placebo (DRUG), Albuterol/salbutamol (DRUG), Beclomethasone dipropionate (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT02031640?

This trial is sponsored by Teva Branded Pharmaceutical Products R&D, which has 103 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT02031640 being conducted?

This trial has 20 study locations across California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial